Is 22nd Century Group a Buy Under $5?

This post was originally published on this site

https://i-invdn-com.investing.com/news/LYNXNPEB9M0BY_M.jpg

However, XXII’s stock price has tumbled 19.9% over the past month. In fact, the stock closed yesterday’s trading session at $4.50, 25.9% below its $6.07 52-week high.

The company has yet to receive the FDA’s approval for its Modified Risk Tobacco Product VLN. And, because favorable federal legislative prospects for cannabis have increased competition in the cannabis space, XXII’s weak financials and high valuation could be a drawback for the stock.

Continue reading on StockNews